Stock market information for Aurinia Pharmaceuticals Inc (AUPH)
- Aurinia Pharmaceuticals Inc is a equity in the USA market.
- The price is 14.58 USD currently with a change of -0.64 USD (-0.04%) from the previous close.
- The latest open price was 15.2 USD and the intraday volume is 957735.
- The intraday high is 15.24 USD and the intraday low is 14.54 USD.
- The latest trade time is Wednesday, February 4, 17:15:00 PST.
Background
Aurinia Pharmaceuticals Inc. is a biopharmaceutical company dedicated to developing therapies for autoimmune diseases with high unmet medical needs. Established in 1993 and headquartered in Edmonton, Alberta, Canada, the company focuses on delivering innovative treatments to improve patient outcomes. In January 2021, Aurinia introduced LUPKYNIS® (voclosporin), the first FDA-approved oral therapy for adult patients with active lupus nephritis. Additionally, the company is developing AUR200, a dual inhibitor targeting B cell-activating factor (BAFF) and a proliferation-inducing ligand (APRIL) for potential treatment of autoimmune diseases.
Key Strategic Focus
Aurinia's strategic focus centers on:
- Core Objectives: Enhancing the standard of care for autoimmune diseases by providing effective and accessible treatments.
- Areas of Specialization: Lupus nephritis and other autoimmune conditions.
- Key Technologies Utilized: Advanced drug development platforms for oral therapies targeting immune pathways.
- Primary Markets Targeted: Global markets, with initial emphasis on North America, Europe, and Japan.
Financials and Funding
As of September 30, 2025, Aurinia reported cash, cash equivalents, restricted cash, and investments totaling $351.8 million, compared to $358.5 million at December 31, 2024. In 2024, the company repurchased 12.2 million common shares for $98.2 million. For the fiscal year 2025, Aurinia anticipates total revenue between $275 million and $280 million, with net product sales projected between $265 million and $270 million.
Pipeline Development
Aurinia's pipeline includes:
- LUPKYNIS® (voclosporin): An oral therapy approved for active lupus nephritis.
- AUR200: A dual inhibitor of BAFF and APRIL, currently in Phase 1 clinical trials for autoimmune diseases. Initial results are expected in the first half of 2025.
Technological Platform and Innovation
Aurinia's technological innovations include:
- Proprietary Technologies: Oral formulations of immunosuppressive agents.
- Significant Scientific Methods: Clinical trial designs focusing on long-term efficacy and safety.
Leadership Team
Aurinia's leadership comprises:
- Peter Greenleaf: President and CEO, with extensive experience in the pharmaceutical industry.
- Craig Johnson: Board member since November 2024, bringing over 30 years of financial management experience in biotechnology.
Leadership Changes
In November 2024, Craig Johnson was appointed to the Board of Directors to support Aurinia's growth initiatives. Dr. Robert T. Foster retired from the Board in the same month.
Strategic Collaborations and Partnerships
Aurinia has a collaboration and licensing agreement with Otsuka Pharmaceutical Co., Ltd. for the development and commercialization of voclosporin in Japan and Europe. This partnership includes upfront payments, milestone payments, and royalties on net sales.
Competitor Profile
- Market Insights and Dynamics: The autoimmune disease treatment market is competitive, with increasing demand for effective therapies.
- Competitor Analysis: Key competitors include GlaxoSmithKline (GSK), AbbVie, Bristol-Myers Squibb (BMS), and Amgen, each offering treatments for autoimmune conditions.
Operational Insights
Aurinia's strategic initiatives focus on:
- Major Competitors: Navigating competition from larger pharmaceutical companies with broader portfolios.
- Market Position: Establishing a strong presence in the lupus nephritis treatment market.
- Competitive Advantages: Specialization in oral therapies for autoimmune diseases.
Strategic Opportunities and Future Directions
Aurinia's roadmap includes:
- Expansion: Broadening the use of LUPKYNIS in additional autoimmune conditions.
- Pipeline Development: Advancing AUR200 through clinical trials.
- Market Penetration: Increasing global market share, particularly in Europe and Japan.
Contact Information
Aurinia Pharmaceuticals Inc.
Official Website:
Social Media:
Headquarters:
